Bryson H M, Spencer C M
Adis International Limited, Auckland, New Zealand.
Drugs. 1996 Sep;52(3):406-15. doi: 10.2165/00003495-199652030-00006.
Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activity against some anaerobes and selected Gram-negative pathogens. Quinupristin-dalfopristin, by way synergism of between its 2 components, is unaffected by most forms of bacterial resistance. Rare forms of macrolide-lincosamide-streptogramin group B resistance may affect its activity; however, at present the incidence of strains with this type of resistance remains low. Quinupristin-dalfopristin is bactericidal against streptococci and staphylococci but has weak or no bactericidal activity against enterococci. In a compassionate use programme, 67% of 95 evaluable patients with vancomycin-resistant Gram-positive infections or intolerant of vancomycin showed improvement with eradication of infection.
奎奴普丁-达福普汀（RP 59500）是一种注射用链阳菌素类抗生素。它对革兰氏阳性菌具有广泛的活性，包括耐甲氧西林葡萄球菌、耐糖肽粪肠球菌和耐青霉素肺炎球菌。奎奴普丁-达福普汀对一些厌氧菌和特定的革兰氏阴性病原体也有活性。通过其两种成分之间的协同作用，奎奴普丁-达福普汀不受大多数形式的细菌耐药性影响。大环内酯-林可酰胺-链阳菌素B组耐药的罕见形式可能会影响其活性；然而，目前这种耐药类型菌株的发生率仍然很低。奎奴普丁-达福普汀对链球菌和葡萄球菌具有杀菌作用，但对肠球菌的杀菌活性较弱或无杀菌活性。在一项同情用药计划中，95例可评估的耐万古霉素革兰氏阳性感染或不耐受万古霉素的患者中，67%的患者感染得到根除且病情有所改善。
